fulvestrant has been researched along with Kidney Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C; Wang, H; Wang, R; Xia, D; Xu, J | 1 |
| Chang, C; Chang, LS; Chen, J; Chen, Y; Doersch, KM; He, D; Hsu, I; Huang, Q; Li, L; Song, W; Yeh, CR; Yeh, S; Zhang, X; Zuo, L | 1 |
| Chun, HY; Jung, YS; Park, BJ; Yoon, MH | 1 |
1 review(s) available for fulvestrant and Kidney Neoplasms
| Article | Year |
|---|---|
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tomography, X-Ray Computed | 2018 |
2 other study(ies) available for fulvestrant and Kidney Neoplasms
| Article | Year |
|---|---|
Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Signal Transduction; Smad3 Protein; Survival Rate; Transforming Growth Factor beta1 | 2018 |
Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; BRCA1 Protein; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fluorescent Antibody Technique, Indirect; Fulvestrant; Genetic Vectors; Humans; Kidney Neoplasms; Microtubule-Organizing Center; Paclitaxel; Rad51 Recombinase; Transfection; Tubulin; Tubulin Modulators; Von Hippel-Lindau Tumor Suppressor Protein | 2014 |